Dodecyltrimethylammonium bromide (DTAB) is a quaternary ammonium surfactant widely used in various applications. Its synthesis typically involves the reaction of dodecylamine with trimethylamine and hydrobromic acid. DTAB exhibits surface activity, forming micelles in aqueous solutions. It has antimicrobial properties and is used as a biocide in various products. Due to its surfactant properties, DTAB is employed in detergents, shampoos, and other cleaning products. It also finds applications in pharmaceuticals, cosmetics, and textile industries. Research on DTAB focuses on its antimicrobial activity, biocompatibility, and environmental impact. The compound is studied for its potential applications in drug delivery systems, gene therapy, and nanotechnology.'
dodecyltrimethylammonium bromide : A quarternary ammonium cation having one dodecyl and three methyl substituents around the central nitrogen. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 14249 |
| CHEMBL ID | 109873 |
| CHEBI ID | 282662 |
| SCHEMBL ID | 56981 |
| MeSH ID | M0314918 |
| Synonym |
|---|
| unii-6ic8nz97s2 |
| 6ic8nz97s2 , |
| 1-dodecanaminium, n,n,n-trimethyl-, bromide (1:1) |
| trimethyllaurylammonium bromide |
| ammonium, dodecyltrimethyl-, bromide |
| dctab |
| dtab (surfactant) |
| n,n,n-trimethyl-1-dodecanaminiuim bromide |
| morpan d |
| ltab |
| n,n,n-trimethyldodecan-1-ammonium bromide |
| dtab |
| einecs 214-290-3 |
| 1-dodecanaminium, n,n,n-trimethyl-, bromide |
| lauryltrimethylammonium bromide |
| trimethyldodecylammonium bromide |
| laurtrimonium bromide |
| dodecyltrimethylammonium bromide |
| ai3-14973 |
| n-lauryl-n,n,n-trimethylammonium bromide |
| fsm 23 |
| dodecyl(trimethyl)azanium bromide |
| CHEMBL109873 , |
| dodecyl-trimethyl-ammonium bromide |
| D1468 |
| 1119-94-4 |
| lauryltrimethylaminium bromide |
| chebi:282662 , |
| ddtmabr |
| n,n,n-trimethyldodecan-1-aminium bromide |
| A802463 |
| dodecyl(trimethyl)ammonium bromide |
| dodecyl trimethyl ammonium bromide |
| NCGC00255995-01 |
| dtxcid3024366 |
| cas-1119-94-4 |
| tox21_302084 |
| dtxsid5044366 , |
| C20389 |
| FT-0604994 |
| JC10040 |
| AKOS015914882 |
| ddtma |
| laurtrimonium bromide [inci] |
| ammonium, dodecyltrimethyl-,bromide |
| SCHEMBL56981 |
| n-dodecyl trimethylammonium bromide |
| dodecyltrimethyl ammonium bromide |
| XJWSAJYUBXQQDR-UHFFFAOYSA-M |
| W-108662 |
| mfcd00011767 |
| lauryltrimethylammonium bromide;ddtma |
| lauryl trimethyl ammonium bromide |
| (1-dodecyl)trimethylammonium bromide |
| dodecyltrimethylammoniumbromide |
| dodecyl(trimethyl)azanium;bromide |
| AS-12886 |
| Q27225722 |
| dodecyltrimethylammonium (bromide) |
| HY-D0838 |
| CS-0014808 |
| Role | Description |
|---|---|
| surfactant | A substance which lowers the surface tension of the medium in which it is dissolved, and/or the interfacial tension with other phases, and, accordingly, is positively adsorbed at the liquid/vapour and/or at other interfaces. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| quaternary ammonium salt | Derivatives of ammonium compounds, (NH4(+))Y(-), in which all four of the hydrogens bonded to nitrogen have been replaced with univalent (usually organyl) groups. |
| bromide salt | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| acetylcholinesterase | Homo sapiens (human) | Potency | 63.2609 | 0.0025 | 41.7960 | 15,848.9004 | AID1347395; AID1347398 |
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 30.8956 | 3.1890 | 29.8841 | 59.4836 | AID1224846 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 20.5105 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
| SMAD family member 2 | Homo sapiens (human) | Potency | 41.2384 | 0.1737 | 34.3047 | 61.8120 | AID1346859; AID1346924 |
| SMAD family member 3 | Homo sapiens (human) | Potency | 41.2384 | 0.1737 | 34.3047 | 61.8120 | AID1346859; AID1346924 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 3.7352 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
| AR protein | Homo sapiens (human) | Potency | 8.7990 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID743035; AID743042; AID743053; AID743054; AID743063 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 47.7534 | 0.0006 | 57.9133 | 22,387.1992 | AID1259377; AID1259378 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 12.1972 | 0.0010 | 22.6508 | 76.6163 | AID1224893 |
| progesterone receptor | Homo sapiens (human) | Potency | 46.1571 | 0.0004 | 17.9460 | 75.1148 | AID1346784; AID1346795 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 25.2790 | 0.0002 | 14.3764 | 60.0339 | AID720691; AID720692 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 54.5043 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159553; AID1159555 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 12.8810 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 5.2880 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 39.9309 | 0.3758 | 27.4851 | 61.6524 | AID743217; AID743220 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 61.1306 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 26.6107 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248; AID1259383; AID743069; AID743075; AID743078; AID743079; AID743080; AID743091 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 33.9046 | 0.0010 | 24.5048 | 61.6448 | AID743212; AID743215 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 46.2271 | 0.0010 | 19.4141 | 70.9645 | AID743140 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 30.6029 | 0.0237 | 23.2282 | 63.5986 | AID743222; AID743223; AID743241 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 21.6899 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 61.6448 | 19.7391 | 45.9784 | 64.9432 | AID1159509 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 7.0241 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 29.2960 | 0.0420 | 27.3789 | 61.6448 | AID743210; AID743228 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 5.3930 | 0.0006 | 27.2152 | 1,122.0200 | AID743202; AID743219 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 30.6379 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 48.5577 | 0.0023 | 19.5956 | 74.0614 | AID651631; AID720552 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 30.6379 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 4.3277 | 0.0119 | 17.9420 | 71.5630 | AID651632 |
| Ataxin-2 | Homo sapiens (human) | Potency | 4.3277 | 0.0119 | 12.2221 | 68.7989 | AID651632 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Dynamin-1 | Homo sapiens (human) | IC50 (µMol) | 16.3200 | 3.1500 | 4.1733 | 5.0000 | AID63727 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID613552 | Antibacterial activity against 5 x 10'5 CFU/mL Escherichia coli ATCC 25922 after 72 hrs by CLSI M07-A8 broth microdilution method | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Bicephalic amphiphile architecture affects antibacterial activity. |
| AID613556 | Antibacterial activity against 5 x 10'5 CFU/mL Enterococcus faecalis ATCC 29212 incubated for 72 hrs followed by growing of cells on trypticase soy agar plate for 24 hrs by CLSI M07-A8 broth microdilution method | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Bicephalic amphiphile architecture affects antibacterial activity. |
| AID613560 | Antibacterial activity against 5 x 10'5 CFU/mL Pseudomonas aeruginosa Boston 41501 ATCC 27853 incubated for 72 hrs followed by growing of cells on trypticase soy agar plate for 24 hrs by CLSI M07-A8 broth microdilution method | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Bicephalic amphiphile architecture affects antibacterial activity. |
| AID1322502 | Induction of biofilm disruption in Staphylococcus aureus after 24 hrs by confocal laser-scanning microscopy | |||
| AID613551 | Antibacterial activity against 5 x 10'5 CFU/mL Pseudomonas aeruginosa Boston 41501 ATCC 27853 after 72 hrs by CLSI M07-A8 broth microdilution method | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Bicephalic amphiphile architecture affects antibacterial activity. |
| AID613559 | Antibacterial activity against 5 x 10'5 CFU/mL Escherichia coli ATCC 25922 incubated for 72 hrs followed by growing of cells on trypticase soy agar plate for 24 hrs by CLSI M07-A8 broth microdilution method | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Bicephalic amphiphile architecture affects antibacterial activity. |
| AID613553 | Antibacterial activity against 5 x 10'5 CFU/mL Enterococcus faecalis ATCC 29212 after 72 hrs by CLSI M07-A8 broth microdilution method | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Bicephalic amphiphile architecture affects antibacterial activity. |
| AID158688 | Inhibitory activity against Plasmodium falciparum | 1997 | Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22 | Antimalarial activity of molecules interfering with Plasmodium falciparum phospholipid metabolism. Structure-activity relationship analysis. |
| AID151197 | In vitro activity against Plasmodium falciparum | 2000 | Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3 | Antimalarial activity of compounds interfering with Plasmodium falciparum phospholipid metabolism: comparison between mono- and bisquaternary ammonium salts. |
| AID63727 | Concentration required against dynamin-1 GTPase activity of sheep brain. | 2004 | Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12 | Long chain amines and long chain ammonium salts as novel inhibitors of dynamin GTPase activity. |
| AID613558 | Antibacterial activity against 5 x 10'5 CFU/mL Staphylococcus aureus subsp. aureus ATCC 29213 incubated for 72 hrs followed by growing of cells on trypticase soy agar plate for 24 hrs by CLSI M07-A8 broth microdilution method | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Bicephalic amphiphile architecture affects antibacterial activity. |
| AID1322503 | Induction of biofilm disruption in Escherichia coli after 24 hrs by confocal laser-scanning microscopy | |||
| AID613554 | Antibacterial activity against 5 x 10'5 CFU/mL Staphylococcus aureus subsp. aureus ATCC 29213 after 72 hrs by CLSI M07-A8 broth microdilution method | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Bicephalic amphiphile architecture affects antibacterial activity. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (39.45) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||